Monitor for initial safety and tolerability data from the Phase 1 trial (NCT07755436) and any future data readouts or partnership expansions for ARR-002. No immediate catalyst beyond the dosing announcement.
Price Chart
Executive Summary
ArriVent BioPharma dosed the first patient in a Phase 1 U.S. trial for ARR-002, a novel first-in-class MUC16/NaPi2b dual-target tetravalent ADC for ovarian and endometrial cancer. This is a routine clinical milestone for a pre-revenue biotech, advancing its second ADC into the clinic and broadening its pipeline beyond lung and GI cancers. No financial data or efficacy results were disclosed.
Key Facts
- First patient dosed in Phase 1 U.S. trial for ARR-002 (NCT07755436), a MUC16/NaPi2b dual-target tetravalent ADC for ovarian and endometrial cancer.
- ARR-002 is ArriVent's second ADC to enter the clinic, following firmonertinib (lead candidate).
- In August 2026, ArriVent entered an exclusive licensing agreement with Shanghai Allist Pharmaceuticals for ARR-002 in Greater China; all other rights retained by ArriVent.
- Preclinical data (AACR 2026, Abstract #2260) showed improved in vitro/in vivo activity over bivalent ADCs; site-specific vcMMAE payload at DAR 4.
- No financial figures, guidance, or revenue data reported in this filing.
Financial Impact
No financial data disclosed; pre-revenue clinical-stage company; no deal values or financial metrics provided.
Risk Factors
- Phase 1 trial may fail to demonstrate safety or efficacy; high attrition risk for early-stage ADCs.
- Dual-target ADC approach is unproven in the clinic; heterogeneous target expression may still limit efficacy.
- No revenue or near-term commercialization; cash runway and dilution risk from ongoing R&D spend.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-115161 |
| Document: tm2627450d1_ex99-1.htm | 0001104659-26-115161 |
| Document: 0001104659-26-115161-index-headers.html | 0001104659-26-115161 |
| Document: 0001104659-26-115161-index.html | 0001104659-26-115161 |
| Document: 0001104659-26-115161.txt | 0001104659-26-115161 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $23.64 | awaiting T+5 | — | $15.69 (−33.63%) |
Oct 25, 2026 1d ago | Press Release | $21.00 | awaiting T+5 | — | $15.69 (−25.29%) |
Oct 23, 2026 2d ago | Press Release | $21.00 | awaiting T+5 | — | $15.69 (−25.29%) |
Oct 19, 2026 7d ago | 8-K | $17.94 | awaiting T+5 | — | $15.69 (−12.54%) |
Oct 13, 2026 12d ago | SC 13G | $16.20 $19.12 | ▲ +18.02% | ▲ +17.57% | $15.69 (−3.15%) |
Oct 13, 2026 13d ago | 8-K | $16.09 $18.85 | ▲ +17.15% | ▲ +18.31% | $15.69 (−2.49%) |
Oct 8, 2026 17d ago | SC 13D/A | $16.73 $16.66 | ▲ +0.42% | ▼ −1.55% | $15.69 (+6.22%) |
Oct 6, 2026 20d ago | 8-K | $15.09 $16.09 | ▼ −6.63% | ▼ −6.77% | $15.69 (−3.98%) |
Aug 12, 2026 10w ago | Press Release | $30.00 $29.18 | ▲ +2.73% | ▲ +0.77% | $15.69 (+47.70%) |
Jun 11, 2026 19w ago | Institutional Cluster | $30.54 $31.74 | ▲ +3.93% | ▲ +3.26% | $15.69 (−48.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers